Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 27 articles:
HTML format



Single Articles


    February 2023
  1. SELBY K, Sedki M, Levine E, Kamineni A, et al
    Test performance metrics for breast, cervical, colon and lung cancer screening: a systematic review.
    J Natl Cancer Inst. 2023 Feb 8:djad028. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  2. SIRUFO MM, Ginaldi L, De Martinis M
    RE: Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Dec 19:djac235. doi: 10.1093.
    PubMed    


    November 2022
  3. HEIDEN BT, Eaton DB, Chang SH, Yan Y, et al
    Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer.
    J Natl Cancer Inst. 2022 Nov 29:djac208. doi: 10.1093.
    PubMed     Abstract available


  4. LI M, Liao K, Chen AJ, Cascone T, et al
    Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
    J Natl Cancer Inst. 2022 Nov 8. pii: 6809139. doi: 10.1093.
    PubMed     Abstract available


  5. DI FEDERICO A, De Giglio A, Gelsomino F, Sperandi F, et al
    Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis.
    J Natl Cancer Inst. 2022 Nov 2. pii: 6794208. doi: 10.1093.
    PubMed     Abstract available


    October 2022
  6. YOU S, Kim M, Hoi XP, Lee YC, et al
    Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
    J Natl Cancer Inst. 2022;114:1380-1391.
    PubMed     Abstract available


    September 2022
  7. WARKENTIN MT, Tammemagi MC, Espin-Garcia O, Budhathoki S, et al
    Lung Cancer Absolute Risk Models for Mortality in Asian Population using China Kadoorie Biobank.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694851. doi: 10.1093.
    PubMed     Abstract available


  8. PELLINEN T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, et al
    Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
    J Natl Cancer Inst. 2022 Sep 9. pii: 6694853. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  9. SEDANI AE, Davis OC, Clifton SC, Campbell JE, et al
    Facilitators and Barriers to Implementation of Lung Cancer Screening: A Framework Driven Systematic Review.
    J Natl Cancer Inst. 2022 Aug 22. pii: 6673083. doi: 10.1093.
    PubMed     Abstract available


  10. VOGTMANN E, Hua X, Yu G, Purandare V, et al
    The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies.
    J Natl Cancer Inst. 2022 Aug 5. pii: 6656358. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  11. BROUWER AF, Engle JM, Jeon J, Meza R, et al
    Sociodemographic survival disparities for lung cancer in the United States, 2000-2016.
    J Natl Cancer Inst. 2022 Jul 22. pii: 6648464. doi: 10.1093.
    PubMed     Abstract available


  12. TAYLOR KL, Williams RM, Li T, Luta G, et al
    A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting.
    J Natl Cancer Inst. 2022 Jul 12. pii: 6633937. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  13. CASTILHO JL, Bian A, Jenkins CA, Shepherd BE, et al
    CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.
    J Natl Cancer Inst. 2022;114:854-862.
    PubMed     Abstract available


    May 2022
  14. GABRIEL AAG, Atkins JR, Penha RCC, Smith-Byrne K, et al
    Genetic analysis of lung cancer and the germline impact on somatic mutation burden.
    J Natl Cancer Inst. 2022 May 2. pii: 6576636. doi: 10.1093.
    PubMed     Abstract available


    April 2022

  15. Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2022 Apr 1. pii: 6561908. doi: 10.1093.
    PubMed    


    February 2022
  16. TANAKA I, Dayde D, Tai MC, Mori H, et al
    SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.
    J Natl Cancer Inst. 2022;114:290-301.
    PubMed     Abstract available


    December 2021
  17. CHOI E, Luo SJ, Aredo JV, Backhus LM, et al
    The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459177. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  18. ISLAMI F, Ward EM, Sung H, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
    J Natl Cancer Inst. 2021;113:1648-1669.
    PubMed     Abstract available


  19. GAVRIELATOU N, Shafi S, Gaule P, Rimm DL, et al
    PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both.
    J Natl Cancer Inst. 2021;113:1613-1614.
    PubMed    


    August 2021
  20. HOPKINS AM, Kichenadasse G, Logan JM, Rowland A, et al
    RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 27. pii: 6358733. doi: 10.1093.
    PubMed    


  21. ZHAO W, Zhu B, Hutchinson A, Pesatori AC, et al
    Clinical Implications of Inter- and Intra-Tumor Heterogeneity of Immune Cell Markers in Lung Cancer.
    J Natl Cancer Inst. 2021 Aug 17. pii: 6353611. doi: 10.1093.
    PubMed     Abstract available


  22. DEROUEN MC, Canchola AJ, Thompson CA, Jin A, et al
    Incidence of Lung Cancer Among Never-Smoking Asian American, Native Hawaiian, and Pacific Islander Females.
    J Natl Cancer Inst. 2021 Aug 4. pii: 6338453. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  23. CHOI E, Sanyal N, Ding VY, Gardner RM, et al
    Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
    J Natl Cancer Inst. 2021 Jul 13. pii: 6320070. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  24. WANG X, Ricciuti B, Alessi JV, Nguyen T, et al
    Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2021 Jun 11. pii: 6296846. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  25. VERHOEVEN DC, Chollette V, Lazzara EH, Shuffler ML, et al
    The Anatomy and Physiology of Teaming in Cancer Care Delivery: A Conceptual Framework.
    J Natl Cancer Inst. 2021;113:360-370.
    PubMed     Abstract available


    December 2020
  26. MITCHELL AP, Bach PB
    Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.
    J Natl Cancer Inst. 2020;112:1177-1178.
    PubMed    


    July 2020
  27. TAKVORIAN SU, Balogh E, Nass S, Valentin VL, et al
    Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action.
    J Natl Cancer Inst. 2020;112:663-670.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: